Compare Kyndryl Holdings Inc (KD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Mesoblast Limited — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Kyndryl Holdings Inc is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 5,354,348). Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Mesoblast Limited for 15 Days on average.
| KD | MESO | |
|---|---|---|
Market Cap | $2.59B | $1.75B |
Volume | 5,354,348 | 239,027 |
Sector | Technology | Health |
52-Week High | $29.76 | $20.96 |
52-Week Low | $10.59 | $13.19 |
Typical Hold Time | 36 Days | 15 Days |
Enterprise Value | $5.41B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
